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Type IIb sodium-phosphate cotransporter (NaPi2b) provides phosphate intake in the cells of some epithelial 
tissues, osteoblasts and odontoblasts. Abnormal expression of NaPi2b has been detected in some types of
epithelial tumors. An alteration in NaPi2b activity, caused by mutations in transporter gene  SLC34A2, has
been recently revealed in patients with pulmonary alveolar microlithiasis, an autosomal recessively
inherited disease, characterized by deposition of calcium-phosphate precipitates in the lungs. In the present 
study we have combined the information about all mutations found to date in the coding sequence of
SLC34A2 and its transcript, compiled their map, and analysed their relevance to the function of NaPi2b. 
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Introduction. Adequate phosphate absorption is an
important process in the maintenance of metabolism at
cellular and organism-wide levels. The transport of
inorganic phosphate in the cells of the mammals is
provided by transporters of three families, NaPi-I,
NaPi-II, and NaPi-III, encoded, respectively, by the
gene families SLC17, SLC34, and SLC20. A member of 
the NaPi-II family, type 2b sodium-phosphate cotrans-
porter  NaPi2b (synonyms: NaPi-IIb, NPT2b; gene
SLC34A2 localized in chromosome site 4p15), is a
tissue-specific transporter which is expressed in a
number of mammalian tissues. Expression on mRNA
level was shown in lungs, small intestine, kidney, liver, 
placenta, pancreas, prostate, ovary, thyroid, uterus,
salivary gland, testis, mammary gland [1,2], while the
expression on protein level was shown only for lungs
[1, 3], epididymis [4], mammary gland [5], salivary
glands [6], liver [7], bones [8], and teeth [9]. NaPi2b is
a transmembrane glycoprotein of 689 or 690 amino
acids residues in length, consisting of eight trans-
membrane domains. The molecular weight of NaPi2b
varies between 77–108 kDa, depending on the
glycosylation status [10].
Recently several studies have suggested NaPi2b as
a potential molecular marker of several types of cancer. 
Initially, NaPi2b overexpression had been linked to  the 
papillary thyroid cancer [11]. Gene expression pro-
filing performed with microarray technology and
quantitative PCR showed that NaPi2b transcripts are
overrepresented in the papillary thyroid cancer cells by
18–49 folds [12]. In the sequel, the transcript of
SLC34A2 was shown to be overrepresented in the
human ovarian cancer cells by serial analysis of gene
expression (SAGE) [13]. Recently, we have identified
NaPi2b as the MX35 antigen, which is overexpressed
in 90 % of all epithelial ovarian cancers [14]. In
contrast to the ovarian and papillary thyroid cancer
cells, in the breast [15] and lung [16] cancer cells the
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are very few studies focused on identification of pos-
sible mutations in SLC34A2 gene in malignant cells.
According to the literature data only three mutations in
the coding sequence of SLC34A2 have been detected
and all of them in the ovarian cancer cell line,
OVARC1 [17], implicating their possible role in tu-
morogenesis. 
In two independent studies, the mutations in
SLC34A2 gene were shown to cause an autosomal re-
cessive hereditary disease, pulmonary alveolar mic-
rolithiasis (PAM), which is characterized by the
deposition of calcium-phosphate microliths in lungs [18, 
19]. Moreover, some patients with testicular microli-
thiasis (TM) were discovered to be heterozygous for
mutations in SLC34A2 [18].
Despite the accumulation of the data concerning
the pathologies associated with the mutations in
SLC34A2, there have been no studies addressing the
analysis of the whole array of polymorphisms
14
LITUIEV D. S., KIYAMOVA R. G. 
Fig. 1. Cotransporter and transmembrane domains topology of the human NaPi2b. Topology of NaPi2b cotransporter domains according to
NCBI Concerved Domain Database (http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml) (1). Topology of NaPi2b transmembrane
domains and the second extracellular loop according to Yin et al. [14] (2). Uniprot KB database prediction service (http://www.uniprot.org)
(3); Field et al. (4)  (= =  – cotransporter domains; – –  – the transmembrane domains; | | |  – cystein residues in a cystein-rich region; xxx – the
second extracellular loop)occurring in the gene of NaPi2b in health and different
pathologies. In order to summarize the current infor-
mation and evaluate a possible role of the NaPi2b
polymorphism in cancer, we have compiled the map of
polymorphisms in the coding sequence of NaPi2b gene
SLC34A2 in genomic and cDNA sequences available
in different databases. 
Models of the NaPi2b transmembrane topology
and domain structure. NaPi2b protein has two
sodium-phosphate cotransport regions that are con-
served among sodium-phosphate cotransporters (Fig.
1): the first region spanning 161 amino acid residues
(109–269) and the second, spanning 159 amino acid
residues (382–540) (NCBI Conserved Domain Data-
base, http://www.ncbi.nlm.nih.gov/Structure/ cdd/cdd. 
shtml). According to the models of NaPi2b transmem-
brane topology it has eight transmembrane domains
with both  N- and C-terminal ends facing the cytoplasm 
and four extracellular loops with multiple glycosyla-
tion sites within the largest (second) one [1, 10, 14, 20,
21]. The position of transmembrane regions and the
large  extracellular loop   are slightly different in these
predicted models.  The extracellular location of   large
loop was confirmed in MHA cell surface binding assay
[14]. 
Recent studies have shown that the glycosylation of 
human NaPi2b is mostly N-linked [14] and six
potential sites for N-glycosylation in the large
extracellular loop (N
294, N
307, N
312, N
320, N
334, N
339 ) have
been predicted [1, 2, 14]. The other member of this
family transporters NaPi-IIa (type IIa sodium-phos-
phate cotransporter, NaPi2a), which is highly homo-
logous to NaPi2b has only two consensus sites for N-
glycosylation (N
298 and N
328) [1, 2]. These data indicate
that posttranslational protein modifications such as
glycosylation could be important for transporters func-
tioning. 
The cytoplasmic C-tail of NaPi2b contains the
polycysteine motif, unique for the type IIb of NaPi co-
transporters, which is a potential site for palmitoylation
[22]. Studies on metabolic labelling followed by
immunoprecipitation confirmed NaPi2b palmitoylation
[14]. The C-terminal amino acids of the protein
(Thr-Ala-Leu) strongly resemble the PDZ
domain-binding motif. In contrast to NaPi-IIa, which
was shown to interact with several PDZ domain
containing proteins [23], the binding partners for
NaPi2b have not been identified so far. It has been
recently demonstrated that the C-terminal leucine of
human NaPi2b is necessary for its apical sorting [22].
Human pathologies of phosphate homeostasis
associated with NaPi2b. Mutations in the gene of
NaPi2b (SLC34A) were identified by two independent
research groups in patients with PAM, a rare hereditary
autosomal recessive disease marked by calcium phos-
phate precipitate deposition in lungs. Corut et al. [18]
implemented the linkage analysis with microsatellite
markers and further single strand conformation
polymorphism (SSCP) analysis. In this study, six exonic 
mutations in SLC34A2 were identified, including a
p.G106R substitution, two missense mutations (p.Q76X
(C226T), p.V448X (del1342G)), frame shifts at 38
th
amino acid (p.del114A) and at 443
rd amino acid
(1328delT), a deletion in promoter exon, and a non-
causative substitution in heterozygous state (p.T330M
(C989T)). In a parallel study, Huqun and co-authors [19] 
identified two frame shifting deletion mutations: p.del
461…519 (del 1381–1557) and p.del 591…596 (del
1772–1789) by means of microarray-based SNP map
ping technique. Altogether, seven causative mutations in 
CDS and one causative mutation in the promoter exon of 
SLC34A2 for PAM have been reported in these studies.
Mutations in SLC34A2 gene were also described in
patients with TM [18], a more frequent calcium-phos-
phate accumulation disease, which is often associated
with infertility and cancer. The screening of fifteen TM 
patients’ samples by SSCP technique revealed only
two of them to carry mutations in heterozygous state.
One patient had a synonymous SNP in the CDS
(T552C) and the other had one SNP in 3'-UTR
(*G27T) of SLC34A2. Both mutations were associated
with infertility and the latter was also associated with
cancer [18]. The authors concluded  that rare mutations
carried by two patients with TM indicated that
SLC34A2 could be responsible for this pathology, at
least in those patients, and noted that others TM pati-
ents might have escape detection because the efficien-
cy of SSCP is not 100 % and mutant variants could
possibly be located in the gene regions which were not
analysed [18].   
The authors also hypothesized that phosphate
transporter NaPi2b could be responsible for calci-
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Mutation position
Source Refe-
r ence
Entry numbers in
Nucleotide
(or/and SNP)
databases
Context
cDNA (ORF) Protein
Non-synonymous SNPs
T134C p.V45A SNP database (genomic DNA) – (rs35426730) Cytoplasmic N-terminus
G316C p.G106R PAM, genomic sequence
(homozygote) [17] – 1
st TMR
C682G p.V228L Small intestine cDNA library [2] AF146796.1 1
st cotransporter domain
A988G & C989T p.T330V OVARC1 cell line cDNA library [19] AK075015.1 2
nd extracellular loop
C989T p.T330M Healthy donor genomic DNA
(single allele) [17] – 2
nd extracellular loop
C1525T p.R509C SNP database (genomic DNA) – (rs34751784) 2
nd cotransporter domain,
intracellular region
G1859A p.C620Y Small intestine or lung cDNA
library [1] AF111856  Cystein-rich region
G1901A p.G634D A genomic entry and SNP
database – AC092436.5
(rs6448389) Cytoplasmic C-terminus
In-frame deletions
del 1381–1557 p.del
461…519 OVARC1 cell line cDNA library [19] AK075046.1 59 aa in 2
nd cotransport, 
6
th TMR
del 1772–1789 p.del
591…596 OVARC1 cell line cDNA library [19] AK075015.1 6 aa in intracellular 
C-terminus
Nonsense mutations
C226T Truncation
Q76X
PAM, genomic sequence
(homozygote) [17] – –
del1342G Truncation
V448X
PAM, genomic sequence
(homozygote) [17] – –
Frame shifting mutations
del114A Frameshift at
38
th aa
PAM, genomic sequence
(homozygote) [17] – –
857–871 del ins AA
GTT ATC GCT TTT
TCA TC
Fframeshift at
268
th aa
PAM, genomic sequence
(homozygote) [18] – –
IVS8 + 1G > A Frameshift
after 349
th aa
PAM, genomic sequence
(homozygote) [18] – (Substitution in introne,
aberrant splicing)
del1328T Frameshift at
443
rd aa
PAM, genomic sequence
(homozygote) [17] – –
Synonymous SNPs
T552C (Ile
184) TM, genomic sequence (single
allele) [17] –
The 3
rd TMR
T1089C (Ala
383) SNP database – (rs34723230) The 4
th TMR
Table 1
Mutations in NaPi2b sequencefication shown in several other tissues such as kidney,
pancreas, prostate, ovary, small intestine, mammary
gland, liver, and placenta where SLC34A2 gene exp-
ression is well documented [2, 18]. 
In this regard it seems very interesting that some tu- 
mours also carry occasional calcifications. In the breast 
and ovarian cancers, calcifications were directly or
circumstantially shown to be calcium-phosphate salts
[24, 25]. Furthermore, calcium-phosphate precipitates
were demonstrated to enhance mitogenesis in the breast 
cancer cell line cultures [26]. The impairment of calci-
um-phosphate homeostasis resulting in such calcifica-
tions in the ovarian and breast cancer tumours can be
presumed to be connected with NaPi2b deregulation
[13, 15]. Undoubtedly, the NaPi2b expression and
polymorphism in tumours, that carry calcifications,
should be further investigated.
Polymorphisms in  SLC34A2 gene: a potential
link to deregulation of NaPi2b function. We have
performed detailed analysis of all known to date sequ-
ence variations in CDS of SLC34A2 gene and gathered
a panel of eight nsSNPs, two sSNPs, two deletions
without frame shift, two nonsense mutations and four
frame shifting mutations (Table 1). Relying on the data
obtained, we have compiled the map of potential
mutations in CDS of human phosphate transporter
NaPi2b (see supplement 1).
Non-synonymous single nucleotide polymor-
phisms. Eight nsSNPs in the gene of human NaPi2b
have been reported to date.
The p.V45A (T134C) substitution in cytoplasmic
N-terminus of NaPi2b according to NCBI SNP
database (http://www.ncbi.nlm.nih.gov/SNP/) is found 
in Sub-Saharan African people with allele frequency of 
0.025 (120 chromosome samples tested, i. e. found in 3
samples) and was not found either in European (120
chromosomes) or Asian (180 chromosomes) popula-
tions. Any phenotypic manifestation of the p.V45A
polymorphism has not been described.
The p.G106R substitution, which results in the in-
troduction of a positively charged amino acid in the
non-polar length of the first transmembrane region (the
first conserved cotransport domain), was identified in
homozygote state in PAM patients [18].
The p.V228L substitution in the cDNA clone
obtained from an enriched human intestinal cDNA
library [2] is located in the first cotransporter domain.
As indicated in Table 2, Val
228 is located in a highly
conservative region of the first cotransporter domain.
Two nsSNP have been found in the position of 330
th
amino acid (Thr
330) of NaPi2b. The p.T330M change-
over was identified in heterozygote state in healthy
donors by Corut and co-authors [18]. The other sub-
stitution at the same site, p.T330V, is present in a
cDNA clone obtained from the human ovarian carci-
noma cell line OVARC1 cDNA library [17]. This re-
placement could be derived from p.T330M by con-
sequent change in the second and the third positions of
the codon:
                             T ® M ® V
                                acg ® aug ® gug.
Corut and co-authors have suggested that the
p.T330M substitution is likely to inactivate the
function of NaPi2b, since it renders the replacement of
a non-polar amino acid for polar one [18]. However,
since this mutation is located outside of the conserved
cotransport domains of NaPi2b and is not strictly
conserved in vertebrates, having amino acids other than 
Thr in two of ten species taken into analysis (Table 2),
we suppose that this mutation does not affect the
function of the transporter. On the other hand, it is
likely to affect the antigenic properties of NaPi2b,
because Thr
330 is located in a highly immunogenic
region [14, 27]. Moreover, we have recently de-
monstrated that the mutation p.T330V abolishes
recognition of NaPi2b by two monoclonal antibodies,
MX35 and anti-NaPi2b L2 (20/3) in Western-blot
analysis [28]. Taking into account the fact that two
mutations have been independently detected in the
same position (Thr
330), it can be assumed to be a
mutational hot spot in the SLC34A gene.
The p.R509C (C1525T) missense mutation in
NCBI SNP database was detected in a single chromo-
some sample from an African American person from a
mixed (Caucasian and Afro-American) set of 74 chro-
mosomes (aggregate allele frequency 0.014). Pheno-
typic manifestation of the polymorphism is unknown. 
The p.C620Y substitution (in a clone obtained from 
human lung cDNA library [1]) is located in the cysteine 
cluster within the cytoplasmic C-tail, which is a
potential site of fatty acid attachment [22] and is unique 
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cotransporters.
The p.G634D (G1901A) variant is located in the
part that is conserved among the terrestrial mammals,
but is absent in fishes. According to NCBI SNP
database (rs6448389), p.634D (G1901) allelic variant
frequency is 0.138–0.188 in European population,
0.043 in Afro-American and it has not been found in
Asian and Sub-Saharan African ones.
Taken together, eight non-synonymous SNPs were
described in SLC34A2, with one of them (p.G106R)
having an established phenotypic manifestation
(pulmonary alveolar microlithiasis).
Synonymous single nucleotide polymorphisms.
Two synonymous SNPs have been described in
SLC34A2  coding sequence, namely T552C (Ile
184) and
T1089C (Ala
383) (Table 1). All two sSNPs are T > C
substitutions in the third position of the codons.
The single allele of T552C (Ile
184) sSNP was
discovered in testicular microlithiasis patients and in
two healthy individuals [18]. Although no causal effect 
of this mutation was proven, authors [18] hypothesized
that this mutation can cause aberrant splicing of the
SLC34A2 transcript by producing an exonic splicing
enhancer sequence. Another explanation for the effect
of this mutation as the one with incomplete penetrance
could be analogous to following. In MDR1 gene
(Multidrug resistance 1) coding for a transporter
protein, «synonymous» substitutions were recently
shown to affect functional activity of the protein, most
likely through alteration of protein biosynthesis
velocity and folding behaviour [29] due to bias in sy-
18
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Position Context
Species
Pseudopleuronectes
americanus Danio rerio Canis familiaris Rattus
norvegicus Mus musculus Bos taurus
45 Cytoplasmic N-terminus – – V V V I
106 1
st transmembrane region G G G G G V
228 1
st cotransport domain V V V V V V
330 2
nd extracellular loop E T S T T T
509 2
nd cotransporter domain R R R R R R
620 Cystein-rich part in
C-terminus C C L C C C
634 Cytoplasmic C-terminus = = G G G G
Table 2
Conservation of polymorphic amino acid positions of NaPi2b in vertebrates
Position Context
Species
Macaca mulatta Pongo pygmaeus Pan troglodytes Homo sapiens
(consensus sequence)
Homo sapiens
(polymorphic variants)
45 Cytoplasmic N-terminus V V V V A
106 1
st transmembrane region G G G G R
228 1
st cotransport domain V V V V L
330 2
nd extracellular loop T T T T V, M
509 2
nd cotransporter domain R R R R C
620 Cystein-rich part in
C-terminus C C C C Y
634 Cytoplasmic C-terminus G G G G Dnonymous tRNA concentrations. Similarly, the
substitution T552C might result in higher susceptibility 
to environmental and/or genetic factors affecting fol-
ding of NaPi2b molecule, declaring itself with in-
complete tolerance. However, taking into account that
T552C allele have been found in healthy individuals as
well the presence of additional factors  may be required
to facilitate the effect of this substitution on NaPi2b
functioning in testicular microlithiasis patients.
Mutations resulting in truncated NaPi2b protein.
The mutations causing the truncation of NaPi2b protein 
were described in PAM patients and comprise a nsSNP
(C226T) [18], a nonsense single-nucleotide deletions
(1342delG) [18], and four frame-shifting mutations:
one intronic SNP causing aberrant splicing (IVS8 +
+ 1G > A) [19], two frame-shifting single-nucleotide
deletions (114delA, 1328delT) [18], and one complex
exonic deletion-insertion (857–871 del ins AA GTT
ATC GCT TTT TCA TC ) [19].
Only two of these mutations, the complex dele-
tion-insertion (857–871 del ins) and the mutation affec- 
ting splicing (IVS8 + 1G > A) were tested functionally
in electrophysiological studies on Xenopus oocytes
[19]. Both of them cause the synthesis of truncated,
lacking cytoplasmic C-terminal and partially the 2
nd
cotransport region, functionally inactive proteins [19].
Expression of such proteins may affect transport of
inorganic phosphate across the apical membrane of
lung alveolar cells in PAM patients resulting in the
accumulation of calcium-phosphate deposits in lungs.
In-frame deletions. Two cDNA clones of NaPi2b
cotransporter obtained from the ovarian cancer cell line
OVARC1 [17] contain deletions that do not shift the
reading frame (del 1381–1557 and del 1772–1789). The
translated sequences of these cDNA clones lack 59 and 6 
amino acids residues correspondingly at the C-terminal
of NaPi2b. Notably, that the largest deletion involves the 
part of the 2
nd cotransport domain of NaPi2b and poten-
tially may affect NaPi2b transport function. 
The detection of two clones with distinct deletions
in the same cell line can be interpreted by presence of
two mutated alleles, heterogeneity of the cell line, or by
posttranscriptional processing. Both deletions are
flanked by short direct repeats, which can be involved in
mechanisms of either classical DNA mutating or of the
posttranscriptional processing. 
Direct repeat are known to participate in the genesis
of classical deletions by means of either replication
slippage, site-specific recombination or others [30]. The
genesis of deletions was also suggested to be mediated
by DNA-interacting proteins that perform improper
ligation of cut fragments [30]. Analysis performed for
the hepta-nucleotide repeats flanking the 59 amino acids
residues long deletion in SLC34A2 CDS showed that
they coincide with the recognition site for topoisomerase 
II and translin (p.del 590–595 aa). Cleavage sites of
translin and topoisomerase II were found to flank a host
of mutations in human cancer cells, implying that these
enzymes could participate in the genesis of chromo-
somal translocations in human cancers [31]. These data
suggest that these mutations are not exclusively random
and could occur in ovarian cancer in vivo as well.
The other possible origin of these deletions could
be posttranscriptional excision, a phenomenon descri-
bed for human and for cereal plants. During aging, in
Alzheimer’s and Down’s diseases, the short direct re-
peats were shown to cause deletions in RNA transcripts 
by means of posttranscriptional processing coined
«misreading». Such deletions are one or two nucleo-
tides long and occur within or closely to contiguous bi-, 
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The short form 689 amino acids residues
The long form 690 amino acids residues
Fig. 2. Alternative splicing of the second and the third exons of
human NaPi2b: A – schematic diagram of the long variant (Feild et
al., 1999); B – schematic diagram of the short variant (Xu et al.,
1999). Pre-mRNA sequences are shown above and mature mRNAs
with translated sequences (with amino acid residues numbered) are
represented belowtri-, and tetra-nucleotide repeats [32]. Furthermore,
short direct repeats were recently discovered to give
rise to posttranscriptional deletions in several genes of
cereals [33, 34]. These deletions span sequences from
28 to 225 nucleotides, and are flanked by short direct
repeats which are from four to ten nucleotides long.
Interestingly, stresses influence switch between
different deletions in transcripts of the same gene [34].
Therefore, deletions flanked by short direct repeats
can arise in vivo at different conditions and pathologies
by means of either classical genomic mutational pro-
cesses or posttranscriptional processing. Studies on
occurrence and frequency of these deletions in NaPi2b
in ovarian cancer cells in vivo along with investigation
of mechanisms underlying the origin of such deletions
in cancer would promote deeper comprehension of
carcinogenesis.
Splice variants. The cDNAs sequences of NaPi2b
phosphate transporter that were first published by two
independent groups [1, 2] differ in length by three
nucleotide residues. The translated sequence of the
clone obtained by Feild and co-authors [1] from human
lung cDNA (AF111856) is longer than the translated
sequence of the clone obtained by Xu and co-authors
[2] (AF146796) from human small intestine cDNA
library by one amino acid residue (690 compared to
689). In addition, it carries a substitution N38T
(aspartate to threonine) and an extra amino acid,
asparagine, inserted after the 38
th amino acid position.
The analysis of SLC34A2 genomic sequences
shows that these two isoforms are splice variants deri-
ved from a common genomic sequence (Fig. 2). The
expression of these two variants is enabled by the pre-
sence of two contiguous acceptor splicing sites (CAG)
in the intron between the exons 2 and 3.
In order to assess the functional consequence of
these variations, we performed prediction of post-
translational modification sites for these variants. The
prediction using NetPhos 2.0 (CBS Prediction Servers
[35]) gave a noticeable difference of score for possible
phosphorylation of Thr
40. The score for the long form is 
0.164 and for the short form is 0.537. Thus, these
isoforms can possibly have different functional
features and this fact requires additional studies.
Conclusion.  In order to consolidate current
information and assess the possible role of NaPi2b
polymorphism in cancer, we have performed analysis
of mutations in the SLC34A2 gene published to date. 
The analysis of existing mutations in SLC34A2
gene revealed that the most of them are associated with
the autosomal recessive inherited disease, pulmonary
alveolar microlithiasis and/or testicular microlithiasis,
which is characterized by accumulation of calcium-
phosphate precipitates in lungs and testis respectively.
Totally, eighteen mutations in the coding sequence of
human NaPi2b have been described. Seven of them ha-
ve been revealed in genomic DNA of PAM patients,
two in genomic DNA of TM patients and healthy indi-
viduals, nine cDNA mutations were retrieved from
NCBI data bases including three of them found in ova-
rian cancer cell line OVARC1. Interesting that almost
all mutations (six out of seven) found in PAM patients
may cause the expression of truncated from C-termi-
nus form of NaPi2b partially or completely lacking of
2
nd cotransporter domain. For two cases it was confir-
med experimentally that the truncated forms of NaPi2b
are functionally inactive [19]. Taking this it into acco-
unt one can presume that other four mutations in PAM
patients may impair NaPi2b transport function as well. 
Mutations involving single nucleotide substitutions 
in genomic DNA of PAM patients hypothetically influ- 
ence NaPi2b transport activity, however, the signifi-
cance of single nucleotide substitutions in genomic
DNA of TM patients, especially those of them that also
occur in  healthy individuals – T552C (Ile
184), should be 
further validated by electrophysiological studies of
NaPi2b transport function.
Despite of the knowledge about abnormal NaPi2b
expression in some types of epithelial ovarian cancers
no information exists to date about mutations in
SLC34A2 gene in malignant cells. The search of NCBI
databases allowed us to find three mutations in cDNA
of NaPi2b only from ovarian cancer cell line OVCAR1.  
Analysis of mutations allowed us to suggest that at least 
one of them – deletion 59 aa may hypothetically affect
NaPi2b transport function since it partially covers the
2
nd co-transport domain of transporter. 
As it was indicated before, according to the litera-
ture data precipitates, similar to microliths in lungs of
PAM patients, were found in breast and ovarian
cancers. This observation could be explained by
alterations in NaPi2b activity in malignant cells as
20
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of mutations in SLC34A2 gene as well.  Since the
calcium-phosphate precipitates were shown to enhance 
mitogenesis in the breast cancers cell lines one may
speculate that among other things impairment of
NaPi2b expression and function can lead to accumula-
tions of the precipitates in the tumours that could in-
fluence tumour growth and progression. The study of
expression profiles and function of wild type and/or
mutant forms of NaPi2b could provide the insight into
the role of NaPi2b in the pathogenesis of some disea-
ses, including malignancies.
Ä. Ñ. Ë³òóºâ, Ð. Ã. Ê³ÿìî  âà
Ìó òàö³¿  â  ãåí³  íàòð³é-ôîñ ôàò íî ãî  êîò ðàí ñïîð òå ðó  ²²b  òèïó 
ëþ äè íè  SLC34A2 
Ðå çþ ìå
Íàòð³é-ôîñ ôàò íèé êîò ðàí ñïîð òåð IIb òèïó (NaPi2b) çà áåç ïå -
÷óº ïî ãëè íàí íÿ ôîñ ôàò³â ó êë³òè íàõ äå ÿ êèõ åï³òåë³àëü íèõ òêà -
íèí, â îñòå  îá  ëàñ  òàõ òà îäîí  òîá  ëàñ  òàõ. Â îêðåìèõ òè  ïàõ åï³-
òåë³àëü  íèõ ïóõ  ëèí ïî  êà  çà  íî çì³íó åêñïðåñ³¿ NaPi2, à òà  êîæ íå  -
ùî äàâ íî  âè ÿâ ëå íî  ïî ðó øåí íÿ  àê òèâ íîñò³  NaPi2b,  çó ìîâ ëåí³
ìó òàö³ÿìè â ãåí³ òðàíñ ïîð òå ðà (SLC34A2), ó ïàö³ºíò³â ç àëü âå -
î ëÿð íèì  ì³êðîë³ò³àçîì  ëå ãåíü  –  çà õâî ðþ âàíí³  ç  àó òî ñîì íî-ðå -
öå ñèâ íèì  òè ïîì  óñïàä êó âàí íÿ,  ïðè  ÿêî ìó  íà êî ïè ÷ó þòü ñÿ  íå-
ðîç  ÷èíí³ êàëüö³é-ôîñ  ôàòí³ ñîë³ â ëå  ãå  íÿõ. Ó ö³é ðî  áîò³ ç³áðà  íî
òà óçà  ãàëü  íå  íî ³íôîð  ìàö³þ ùîäî âñ³õ ìó  òàö³é, çíàé  äå  íèõ ó êî  -
äó þ÷³é ä³ëÿíö³ ãåíà SLC34A2 ³ éîãî òðàíñ  êðèïò³â, òà îá ãî âî ðå -
íî äàí³ ñòîñîâíî ¿õíüîãî âïëèâó íà ôóíêö³þ NaPi2b.
Êëþ÷oâ³ ñëî âà: ãåí SLC34A2, òðàíñ ïîðò íå îðãàí³÷íî ãî ôîñ -
ôà òó,  àëü âå î ëÿð íèé  ì³êðîë³ò³àç  ëå ãåíü,  ìó òàö³¿,  ðàê  ÿº÷íè êà.
Ä. Ñ. Ëè  òó  åâ, Ð. Ã. Êè  ÿ  ìî  âà
Ìó òà öèè  â  ãåíå  íà òðèé-ôîñ ôàò íî ãî  êîò ðàí ñïîð òå ðà  ²²b  òèïà
÷å ëî âå êà  SLC34A2 
Ðå çþ ìå
Íàò ðèé-ôîñ ôàò íûé  êîò ðàí ñïîð òåð  IIb  òèïà  (NaPi2b)  îá åñ -
ïå ÷è âà åò  ïî ãëî ùå íèå  ôîñ ôà òîâ  â  êëåò êàõ  íå êî òî ðûõ  ýïè òå -
ëè àëü íûõ  òêà íåé,  îñòå îá ëàñ òàõ  è  îäîí òîá ëàñ òàõ.  Â  íåêî-
òî ðûõ òè ïàõ  ýïè òå ëè àëü íûõ îïó õî ëåé ïî êà çà íî èç ìå íå íèå ýêñ -
ïðåñ ñèè  NaPi2,  à  òàê æå  íå äàâ íî  âû ÿâ ëå íû  íà ðó øå íèÿ  àê òèâ -
íîñ òè  NaPi2b,  âû çâàí íûå  ìó òà öè ÿ ìè  â  ãåíå  òðàíñ ïîð òå ðà
(SLC34A),  ó  ïà öè åí òîâ  ñ  àëü âå î ëÿð íûì  ìèê ðî ëè òè à çîì  ëåã -
êèõ  –  çà áî ëå âà íèè  ñ  àó òî ñîì íî-ðå öåñ ñèâ íûì  òè ïîì  íà ñëå äî âà -
íèÿ, ïðè êî òî ðîì  â  ëåã êèõ íà êàï ëè âà þò ñÿ  íå ðàñ òâî ðè ìûå  êàëü 
öèé-ôîñ ôàò íûå  ñîëè.  Â  äàí íîé  ðà áî òå  ñî áðà íà  èí ôîð ìà öèÿ  î
ìó òà öè ÿõ,  îá íà ðó æåí íûõ  â  êî äè ðó þ ùåì  ó÷àñ òêå  ãåíà
SLC34A2 è åãî òðàíñ  êðèï  òàõ, è îá  ñóæ  äà  þò  ñÿ äàí  íûå îá èõ
âëè  ÿ  íèè  íà ôóíê  öèþ NaPi2b.
Êëþ ÷å âûå  ñëî âà:  ãåí  SLC34A2,  òðàíñ ïîðò  íå îðãà íè ÷åñ êî ãî
ôîñ ôà òà,  àëü âå î ëÿð íûé  ìèê ðî ëè òè àç  ëåãêèõ,  ìó òà öèè,  ðàê
ÿè÷ íè êà.
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